Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | DYRK1A | Q13627 | 13/20 | 1.00 |
| ▸ | DYRK2 | Q92630 | 13/20 | 1.00 |
| ▸ | DYRK1B | Q9Y463 | 13/20 | 1.00 |
| ▸ | CCNT1 | O60563 | 11/20 | 1.00 |
| ▸ | CDK9 | P50750 | 11/20 | 1.00 |
| ▸ | CDK5 | Q00535 | 11/20 | 1.00 |
| ▸ | CDK5R1 | Q15078 | 11/20 | 1.00 |
| ▸ | DYRK3 | O43781 | 11/20 | 1.00 |
| ▸ | CCNA2 | P20248 | 9/20 | 1.00 |
| ▸ | CDK2 | P24941 | 9/20 | 1.00 |
| ▸ | FYN | P06241 | 6/20 | 0.74 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL102940 | 0.88 | FYN (0.79) | DYRK1ADYRK2DYRK1BCCNT1CDK9 | |
| SCHEMBL102955 | 0.88 | DYRK1A (1.00) | DYRK1ADYRK2DYRK1BCCNT1CDK9 | |
| SCHEMBL102952 | 0.86 | FYN (0.77) | DYRK1ADYRK2DYRK1BCCNT1CDK9 | |
| SCHEMBL18613549 | 0.85 | FYN (1.00) | DYRK1ADYRK2DYRK1BCCNT1CDK9 | |
| SCHEMBL102984 | 0.85 | FYN (0.79) | DYRK1ADYRK2DYRK1BCCNT1CDK9 | |
| SCHEMBL102507 | 0.85 | FYN (0.79) | DYRK1ADYRK2DYRK1BCCNT1CDK9 | |
| SCHEMBL2942425 | 0.83 | FYN (1.00) | DYRK1ADYRK2DYRK1BCCNT1CDK9 | |
| SCHEMBL102225 | 0.83 | FYN (0.76) | DYRK1ADYRK2DYRK1BCCNT1CDK9 | |
| SCHEMBL21067856 | 0.83 | DYRK1A (0.78) | DYRK1ADYRK2DYRK1BCCNT1CDK9 | |
| SCHEMBL2950363 | 0.83 | DYRK1A (0.78) | DYRK1ADYRK2DYRK1BCCNT1CDK9 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8710057-B2 | Imidazo[1,2-B]pyridazine and pyrazolo[1 .5-A]pyrimidine derivatives and their use as protein kinase inhibitors | TOLERO PHARMACEUTICALS, INC. (US) | 2014-04-29 | — | — | US | disclosed |
| US-8710057-B2 | Imidazo[1,2-B]pyridazine and pyrazolo[1 .5-A]pyrimidine derivatives and their use as protein kinase inhibitors | TOLERO PHARMACEUTICALS, INC. (US) | 2014-04-29 | — | — | US | disclosed |
| US-20120058997-A1 | IMIDAZO[1,2-B]PYRIDAZINE AND PYRAZOLO[1,5-A]PYRIMIDINE DERIVATIVES AND THEIR USE AS PROTEIN KINASE INHIBITORS | SUPERGEN, INC. (US) | 2012-03-08 | — | — | US | disclosed |
| US-20120058997-A1 | IMIDAZO[1,2-B]PYRIDAZINE AND PYRAZOLO[1,5-A]PYRIMIDINE DERIVATIVES AND THEIR USE AS PROTEIN KINASE INHIBITORS | SUPERGEN, INC. (US) | 2012-03-08 | — | — | US | disclosed |
| US-20110281863-A1 | IMIDAZO[1,2-B]PYRIDAZINE AND PYRAZOLO[1,5-A]PYRIMIDINE DERIVATIVES AND THEIR USE AS PROTEIN KINASE INHIBITORS | SUPERGEN, INC. (US) | 2011-11-17 | — | — | US | disclosed |
| US-20110281863-A1 | IMIDAZO[1,2-B]PYRIDAZINE AND PYRAZOLO[1,5-A]PYRIMIDINE DERIVATIVES AND THEIR USE AS PROTEIN KINASE INHIBITORS | SUPERGEN, INC. (US) | 2011-11-17 | — | — | US | disclosed |
| US-20100227861-A1 | IMIDAZO[1,2-beta]PYRIDAZINE AND PYRAZOLO[1,5-alpha]PYRIMIDINE DERIVATIVES AND THEIR USE AS PROTEIN KINASE INHIBITORS | SUPERGEN, INC. (US) | 2010-09-09 | — | — | US | disclosed |
| US-7750007-B2 | Imidazo[1,2-beta]pyridazine and pyrazolo[1,5-alpha]pyrimidine derivatives and their use as protein kinase inhibitors | SUPERGEN, INC. (US) | 2010-07-06 | — | — | US | disclosed |
| US-20080261988-A1 | IMIDAZO[1,2-beta]PYRIDAZINE AND PYRAZOLO[1,5-alpha]PYRIMIDINE DERIVATIVES AND THEIR USE AS PROTEIN KINASE INHIBITORS | SUPERGEN, INC. (US) | 2008-10-23 | — | — | US | disclosed |
| WO-2008058126-A2 | IMIDAZO[1,2-B]PYRIDAZINE AND PYRAZOLO[1,5-A]PYRIMIDINE DERIVATIVES AND THEIR USE AS PROTEIN KINASE INHIBITORS | SUPERGEN, INC. (US) | 2008-05-15 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120058997-A1 | IMIDAZO[1,2-B]PYRIDAZINE AND PYRAZOLO[1,5-A]PYRIMIDINE DERIVATIVES AND THEIR USE AS PROTEIN KINASE INHIBITORS | PIM1, PIM2, PIM3 | DYRK1A 184/4885DYRK2 199/4885DYRK1B 185/4885 |
| US-20110281863-A1 | IMIDAZO[1,2-B]PYRIDAZINE AND PYRAZOLO[1,5-A]PYRIMIDINE DERIVATIVES AND THEIR USE AS PROTEIN KINASE INHIBITORS | PIM1, PIM2, PIM3 | DYRK1A 184/4885DYRK2 199/4885DYRK1B 185/4885 |
| US-20080261988-A1 | IMIDAZO[1,2-beta]PYRIDAZINE AND PYRAZOLO[1,5-alpha]PYRIMIDINE DERIVATIVES AND THEIR USE AS PROTEIN KINASE INHIBITORS | PIM1, PIM2, PIM3 | DYRK1A 221/4885DYRK2 229/4885DYRK1B 235/4885 |
| US-20100227861-A1 | IMIDAZO[1,2-beta]PYRIDAZINE AND PYRAZOLO[1,5-alpha]PYRIMIDINE DERIVATIVES AND THEIR USE AS PROTEIN KINASE INHIBITORS | PIM1, PIM2, PIM3 | DYRK1A 221/4885DYRK2 229/4885DYRK1B 235/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.